NCT00698347

Brief Summary

The purpose of this prospective clinical data collection is to document the performance and clinical outcomes of the M2a-Magnum™ Hip System

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
249

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2004

Longer than P75 for all trials

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2004

Completed
3.6 years until next milestone

First Submitted

Initial submission to the registry

June 13, 2008

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 17, 2008

Completed
6.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2015

Completed
Last Updated

June 21, 2017

Status Verified

June 1, 2017

Enrollment Period

10.2 years

First QC Date

June 13, 2008

Last Update Submit

June 19, 2017

Conditions

Keywords

Total Knee ReplacementTotal Knee ArthroplastyHip Arthritis

Outcome Measures

Primary Outcomes (1)

  • Harris Hip Score

    10 years

Secondary Outcomes (2)

  • Incidence of revisions, removals, and/or complications

    Any time

  • X-Rays

    10 years

Study Arms (1)

M2a-Magnum™ Hip System

Patients who received the M2a-Magnum™ Hip System

Device: M2a-Magnum™ Hip System

Interventions

Also known as: Magnum Hip
M2a-Magnum™ Hip System

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients that have already made the decision to undergo Total Hip Replacement and will receive the M2a-Magnum™ Hip System

You may qualify if:

  • Non-inflammatory degenerative joint disease including: Avascular Necrosis, Diastrophic Variant, Fracture of the Pelvis, Fused Hip, Leg Perthes, Osteoarthritis, Slipped Capital Epiphysis, Subcapital Fractures, Traumatic Arthritis
  • Rheumatoid Arthritis
  • Correction of Functional Deformity
  • Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
  • Revision of previously failed total hip arthroplasty

You may not qualify if:

  • Absolute contraindications include:
  • Infection, Sepsis, and Osteomyelitis
  • Relative contraindications include:
  • Uncooperative patient or patient with neurologic disorders that are incapable of following directions
  • Osteoporosis
  • Metabolic disorders which may impair bone formation
  • Osteomalacia
  • Distant foci of infections which may spread to the implant site
  • Rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram
  • Vascular insufficiency, muscular atrophy, or neuromuscular disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Osteoarthritis, HipArthritisArthritis, RheumatoidJoint DiseasesBone Diseases

Condition Hierarchy (Ancestors)

OsteoarthritisMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Russell Schenck, PhD

    Clinical Research, Biomet Orthopedics, LLC

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 13, 2008

First Posted

June 17, 2008

Study Start

November 1, 2004

Primary Completion

January 1, 2015

Study Completion

January 1, 2015

Last Updated

June 21, 2017

Record last verified: 2017-06